Preview

Онкологическая колопроктология

Расширенный поиск

МИКРОБИОТА, ИММУННАЯ СИСТЕМА И КОЛОРЕКТАЛЬНЫЙ РАК

https://doi.org/10.17650/2220-3478-2017-7-4-11-19

Полный текст:

Аннотация

В статье кратко рассматриваются физиологические аспекты микробиоты кишечника человека, связь дисбиоза с колоректальным раком (КРР), нарушения иммунной системы при развитии КРР, механизмы избегания опухолью иммунного надзора, варианты генетической нестабильности при КРР, коллизии и перспективы иммунотерапии при КРР.

Об авторах

Е. П. Харченко
ФГБУН «Институт эволюционной физиологии и биохимии им. И.М. Сеченова» РАН
Россия

Евгений Петрович Харченко.

194223 Санкт-Петербург, проспект Тореза, 44



И. А. Соловьев
ФГБВОУ ВПО «Военно-медицинская академия им. С.М. Кирова» Минобороны России
Россия

194044 Санкт-Петербург, ул. Академика Лебедева, 6



Список литературы

1. De Rosa M., Rega D., Costabile V. et al. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Ther Adv Gastroenterol 2016;9(6):861–86. DOI: 10.1177/1756283X16659790.

2. Харченко E.П. Канцерогенез: иммунная система и иммунотерапия. Иммунология 2011;32(1):50–6. [Kharchenko E.P. Carcinogenesis: the immune system and immunotherapy. Immunologiya = Immunology 2011;32(1):50–6. (In Russ.)].

3. Irrazábal T., Belcheva A., Girardin S.E. et al. The multifaceted role of the intestinal microbiota in colon cancer. Molecular Cell 2014;54(2):309–20. DOI: 10.1016/j.molcel.2014.03.039.

4. Makkouk A., Weiner G.J. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2014;75(1):5–10. DOI: 10.1158/0008-5472.CAN-14-2538.

5. Ha C., Lam Y.Y., Holmes A.J. Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health. World J Gastroenterol 2014;20(44):16498–517. DOI: 10.3748/wjg.v20.i44.16498.

6. Pflughoeft K.J., Versalovic J. Human microbiome in health and disease. Annu Rev Pathol 2012;7:99–122. DOI: 10.1146/annurev-pathol-011811-132421.

7. McDermott A.J., Huffnagle G.B. The microbiome and regulation of mucosal immunity. Immunology 2013;142(1):24–31. DOI: 10.1111/imm.12231.

8. Jandhyala S.M., Talukdar R., Subramanyam C. et al. Role of the normal gut microbiota World J Gastroenterol 2015;21(29):8787–803. DOI: 10.3748/wjg.v21.i29.8787.

9. Dzutsev A., Goldszmid R.S., Viaud S. et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015;45(1):17–31. DOI: 10.1002/eji.201444972.

10. Cadwell K. The virome in host health and disease. Immunity 2015;42(5):805–13. DOI: 10.1016/j.immuni.2015.05.003.

11. Gagnière J., Raisch J., Veziant J. et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016;22(2):501–18. DOI: 10.3748/wjg.v22.i2.501.

12. Tojo R., Suárez A., Clemente M.G. et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014;20(41):15163–76. DOI: 10.3748/wjg.v20.i41.15163.

13. Bäumler A.J., Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016;535(7610):85–93. DOI: 10.1038/nature18849.

14. Eloe-Fadrosh E.A., Rasko D.A. The human microbiome: from symbiosis to pathogenesis. Annu Rev Med 2013;64:145–63. DOI: 10.1146/annurev-med-010312-133513.

15. Forbes J.D., Van Domselaar G., Bernstein C.N. The gut microbiota in immunemediated inflammatory diseases. Front Microbiol 2016;7:1081. DOI: 10.3389/fmicb.2016.01081.

16. Peterson C.T., Sharma V., Elmén L., Peterson S.N. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol 2014;179(3):363–77. DOI: 10.1111/cei.12474.

17. Muszer M., Noszczyńska M., Kasperkiewicz K. et al. Human microbiome: when a friend becomes an enemy. Arch Immunol Ther Exp 2015;63(4):287–98. DOI: 10.1007/s00005-015-0332-3.

18. Fardini Y., Wang X., Temoin S. et al. Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol 2011;82(6):1468–80. DOI: 10.1111/j.1365-2958.2011.07905.x.

19. Rubinstein M.R., Wang X., Liu W. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/b-catenin signaling via its FadA adhesin. Cell Host Microbe 2013;14(2):195–206. DOI: 10.1016/j.chom.2013.07.012.

20. Wu S., Morin P.J., Maouyo D. et al. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology 2003;124(2):392–400. DOI: 10.1053/gast.2003.50047.

21. Lundberg J.O., Weitzberg E., Cole J.A. et al. Nitrate, bacteria and human health. Nat Rev Microbiol 2004;2(7):593–602. DOI: 10.1038/nrmicro929.

22. Sobko T., Huang L., Midtvedt T. et al. Generation of NO by probiotic bacteria in the gastrointestinal tract. Free Radic Biol Med 2006;41(6):985–91. DOI: 10.1016/j.freeradbiomed.2006.06.020.

23. Huycke M.M., Moore D.R. In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation. Free Radic Biol Med 2002;33(6):818–26.

24. Arthur J.C., Perez-Chanona E., Muhlbauer M. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338(6103):120–3. DOI: 10.1126/science.1224820.

25. Carman R.J., van Tassell R.L., Kingston D.G. et al. Conversion of IQ, a dietary pyrolysis carcinogen to a direct-acting mutagen by normal intestinal bacteria of humans. Mutat Res 1988;206(3):335–42.

26. De Kok T.M., van Maanen J.M., Lankelma J. et al. Electron spin resonance spectroscopy of oxygen radicals generated by synthetic fecapentaene-12 and reduction of fecapentaene mutagenicity to Salmonella typhimurium by hydroxyl radical scavenging. Carcinogenesis 1992;13(7):1249–55. PMID: 1322251.

27. Salaspuro M. Bacteriocolonic pathway for ethanol oxidation: characteristics and implications. Ann Med 1996;28(3):195–200. PMID: 8811162.

28. Choi S.W., Mason J.B. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 2002;132(8 suppl):2413S–8S. PMID: 12163703.

29. Deplancke B., Finster K., Graham W.V. et al. Gastrointestinal and microbial responses to sulfate supplemented drinking water in mice. Exp Biol Med (Maywood) 2003;228(4):424–33. PMID: 12671187.

30. Christl S.U., Scheppach W., Kasper H. Hydrogen metabolism in the large intestine – physiology and clinical implications. Z Gastroenterol 1995;33(7):408–13. PMID: 7571760.

31. Gill C.I., Rowland I.R. Diet and cancer: assessing the risk. Br J Nutr 2002;88(suppl 1): S73–87. DOI: 10.1079/BJN2002632.

32. Hague A., Manning A.M., Hanlon K.A. et al. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993;55(3):498–505. PMID: 8397167.

33. Caderni G., De Filippo C., Luceri et al. Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis 2000;21(11):1965–9. PMID: 11062155.

34. Yamamoto M., Matsumoto S. Gut microbiota and colorectal cancer. Genes Environ 2016;38:11. DOI: 10.1186/s41021-016-0038-8.

35. Formica V., Cereda V., Nardecchia A. et al. Immune reaction and colorectal cancer: friends or foes? World J Gastroenterol 2014;20(35):12407–19. DOI: 10.3748/wjg.v20.i35.12407.

36. Pernot S., Terme M., Voron T. et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014;20(14):3738–50. DOI: 10.3748/wjg.v20.i14.3738.

37. De Vries N.L., Swets M., Vahrmeijer A.L. et al. The immunogenicity of colorectal cancer in relation to tumor development and treatment. Int J Mol Sci 2016;17(7):1030. DOI:10.3390/ijms17071030.

38. Mármol I., Sánchez-de-Diego C., Pradilla Dieste A. et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 2017;18(1):E197. DOI: 10.3390/ijms18010197.

39. Ballester V., Rashtak S., Boardman L. Clinical and molecular features of youngonset colorectal cancer. World J Gastroenterol 2016;22(5):1736–44. DOI: 10.3748/wjg.v22.i5.1736.

40. Rodriguez-Salasa N., Dominguezb G., Barderasc R. et al. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol 2017;109:9–19. DOI: 10.1016/j.critrevonc.2016.11.007.

41. Aghagolzadeh P., Radpour R. New trends in molecular and cellular biomarker discovery for colorectal cancer. World J Gastroenterol 2016;22(25):5678–93. DOI: 10.3748/wjg.v22.i25.5678.

42. Patel A., Tripathi G., Gopalakrishnan K. Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol 2015;21(13):3763–72. DOI: 10.3748/wjg.v21.i13.3763.

43. Podlaha O., Riester M., De S., Michor F. Evolution of the cancer genome. Trends Genet 2012;28(4):155–63. DOI: 10.1016/j.tig.2012.01.003.

44. Joyce J.A., Fearon D.T. T-cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348(6230): 74–80. DOI: 10.1126/science.aaa6204.

45. Palucka A.K., Coussens L.M. The basis of oncoimmunology. Cell 2016;164(6): 1233–47. DOI: 10.1016/j.cell.2016.01.049.

46. Харченко E.П. Иммунное узнавание и иммунная привилегия. Иммунология 2008;29(2):118–24. [Kharchenko E.P. Immune recognition and immune privilege. Immunologiya = Immunology 2008;29(2):118–24. (In Russ.)].

47. Харченко Е.П. Иммунная привилегия: патологический aспект. Иммунология 2009;30(4):249–55. [Kharchenko E.P. Immune privilege: a pathological aspect. Immunologiya = Immunology 2009;30(4):249–55. (In Russ.)].

48. Suntsova M., Garazha A., Ivanova A. et al. Molecular functions of human endogenous retroviruses in health and disease. Cell Mol Life Sci 2015;72(19):3653–75. DOI: 10.1007/s00018-015-1947-6.

49. Philippe P., Mullins C.S., Naville M. et al. Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget 2015;6(37):40095–50111. DOI: 10.18632/oncotarget.5539.

50. Díaz-Carballo D., Acikelli A.H., Klein J. et al. Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. J Exp Clin Cancer Res 2015;34:81. DOI 10.1186/s13046-015-0199-5.

51. Harrison M.M., Jenkins B.V., O’ConnorGiles K.M. et al. A CRISPR view of development. Genes Dev 2016;28(17): 1859–72. DOI: 10.1101/gad.248252.114.


Для цитирования:


Харченко Е.П., Соловьев И.А. МИКРОБИОТА, ИММУННАЯ СИСТЕМА И КОЛОРЕКТАЛЬНЫЙ РАК. Онкологическая колопроктология. 2017;7(4):11-19. https://doi.org/10.17650/2220-3478-2017-7-4-11-19

For citation:


Kharchenko E.P., Solov’ev I.A. MICROBIOTA, IMMUNE SYSTEM AND COLORECTAL CANCER. Colorectal Oncology. 2017;7(4):11-19. (In Russ.) https://doi.org/10.17650/2220-3478-2017-7-4-11-19

Просмотров: 203


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2220-3478 (Print)
ISSN 2413-0583 (Online)